Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutetinib versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer with uncommon non-resistant EGFR mutations
CTR20252804Phase 3Active
- Sponsor
- Suzhong Pharmaceutical Group
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sutetinib malate in non-small cell lung cancer (NSCLC), sponsored by Suzhong Pharmaceutical Group. Started Jul 2025; status: active.
02
Drugs
sutetinib malate
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252804.